ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1.
Renschler JP, Walters KM, Newton PN, Laxminarayan R, 2015. Estimated under-five deaths associated with poor-quality antimalarials in sub-Saharan African. Am J Trop Med Hyg 92: 119–126.
-
2.
WHO, 2017. A Study on the Public Health and Socioeconomic Impact of Substandard and Falsified Medical Products. Geneva, Switzerland: World Health Organization . License: CC BY-NC-SA 3.0 IGO.
-
3.
Ozawa S, Evans DR, Bessias S, Haynie DG, Yemeke TT, Laing SK, Herrington JE, 2018. Prevalence and estimated economic burden of substandard and falsified medicines in low- and middle-income countries: a systematic review and meta-analysis. JAMA Netw Open 1: e181662.
-
4.
WHO, 2017. WHO Global Surveillance and Monitoring System for Substandard and Falsified Medical Products. Geneva, Switzerland: World Health organization . License: CC BY- NC-SA 3.0 IGO. Available at: http://www.who.int/medicines/regulation/ssffc/publications/GSMS_Report.pdf. Accessed September 18, 2018.
-
5.
Ozawa S, Evans DR, Higgins CR, Lang SK, Awor P, 2019. Development of an agent-based model to assess the impact of substandard and falsified anti-malarials: Uganda case study. Malar J 18: 5.
-
6.
WHO, 2016. WHO Global Surveillance and Monitoring System SSFFC Medical Products. Technical Briefing. Available at: http://www.who.int/medicines/technical_briefing/tbs/TBS2016_SSFFC_Products.pdf. Accessed January 24, 2018.
-
7.
Newton PN et al. 2019. Oxford Statement. Available at: https://medswecantrust.org/Oxford-statement. Accessed February 15, 2019.
-
8.
WHO, 2016. Annual Report. WHO Essential Medicines and Health Products. Available at: http://www.who.int/medicines/publications/annual-reports/WHO_EMP_Report_2016_Online.pdf. Accessed September 20, 2018.
-
9.
WHO, 2017. Seventieth World Health Assembly Update, 29 May 2017. Available at: http://www.who.int/mediacentre/news/releases/2017/dementia-immunization-refuguees/en/. Accessed September 18, 2018.
-
10.
WHO, 2017. WHO Member State Mechanism on Substandard/Spurious/Falselylabelled/Falsified/Counterfeit (SSFFC) Medical Products. Available at: http://www.who.int/medicines/regulation/ssffc/A70_23-en1.pdf. Accessed September 18, 2018.
-
11.
WHO, 2017. A New Model for Regulatory System Strengthening. Available at: http://www.who.int/medicines/areas/quality_safety/regulation_legislation/rss_new-model/en/. Accessed September 20, 2018.
-
12.
International Association of Pharmaceutical Manufacturers and Associations (IFPMA), 2018. Falsified Medicines. Available at: https://www.ifpma.org/topics/falsified-medicines/. Accessed September 20, 2018.
-
13.
Mackey TK, Liang BA, York P, Kubic T, 2015. Counterfeit drug penetration into global legitimate medicine supply chains: a global assessment. Am J Trop Med Hyg 92: 59–67.
-
14.
Nayyar GML, Attaran A, Clark JP, Culzoni MJ, Fernandez FM, Herrington JE, Kendall M, Newton PN, Breman JG, 2015. Responding to the pandemic of falsified medicines. Am J Trop Med Hyg 92: 113–118.
-
15.
Nayyar GM, Breman JG, Newton PN, Herrington J, 2012. Poor-quality antimalarial drugs in southeast Asia and sub-Saharan Africa. Lancet Infect Dis 12: 488–496.
-
16.
Newton PN, Hanson K, Goodman C; ACTwatch Group, 2017. Do anti-malarials in Africa meet quality standards? The market penetration of non quality-assured artemisinin combination therapy in eight African countries. Malar J 16: 204–236.
-
17.
Newton PN, Green MD, Fernandez FM, 2010. Impact of poor quality medicines in the developing world. Trends Pharmacol Sci 31: 99–101.
-
18.
USP, 2017. Promoting the Quality of Medicines (PQM). Available at: http://www.usp-pqm.org/about. Accessed September 20, 2018.
-
19.
WWARN, 2018. Antimalarial Quality Surveyor. Available at: http://www.wwarn.org/aq-surveyor. Accessed September 20, 2018.
-
20.
Weinstein ZB, Zaman MH, 2019. Evolution of Rifampin resistance in Escherichia coli and Mycobacterium smegmatis due to substandard drugs. Antimicrob Agents Chemother: e01243- 18.
-
21.
Davies J, Davies DO, 2010. Origins and evolution of antibiotic resistance. Microbiol Mol Biol Rev 74: 417–433.
-
22.
Antignac M, Diop BI, Do B, N’Guetta R, Toure IA, Zabsonre P, Jouven X, 2017. Quality assessment of 7 cardiovascular drugs in 10 sub-Saharan countries: the SEVEN study. JAMA Cardiol 2: 223–225.
-
23.
WHO, 2017. Medical Product Alert N° 3/2017–Falsified Avastin (Bevacizumab) and Sutent (Sunitinib Malate) Circulating in East Africa. Available at: http://www.who.int/medicines/publications/drugalerts/drug_alert3-2017/en/. Accessed September 20, 2018.
-
24.
WHO, 2017. Medical Product Alert N° 4/2017–Falsified Penicillin V Circulating in Cameroon. Available at: http://www.who.int/medicines/publications/drugalerts/drug_alert4-2017/en/. Accessed September 20, 2018.
-
25.
WHO, 2017. Medical Product Alert N° 2/2016–Falsified AMARIL Yellow Fever Vaccines Circulating in South East Asia. Available at: http://www.who.int/medicines/publications/drugalerts/Alert2_2016_Fev_Falsified_AMARILyellow-fever-vaccine_searo_en.pdf. Accessed September 20, 2018.
-
26.
WHO, 2017. Medical Product Alert N° 1/2017–Falsified Meningococcal ACWY Vaccine Circulating in West Africa. Available at: http://www.who.int/medicines/publications/drugalerts/WHO_ALERTn1.2017_Falsified_meningitisVaccineNiger.pdf?ua=1. Accessed September 20, 2018.
-
27.
WHO, 2017. Antimicrobial Resistance. Available at: http://www.who.int/mediacentre/factsheets/fs194/en/. Accessed September 20, 2018.
-
28.
Gallagher JC, Colaizzi JL, 2000. Issues in internet pharmacy practice. Ann Pharmacother 34: 1483–1485.
-
29.
CSIP, 2016. The Internet Pharmacy Market in 2016: Trends, Challenges, and Opportunities. Available at: https://safemedsonline.org/resource/the-internet-pharmacy-market-in-2016-trends-challenges-and-opportunities/. Accessed September 20, 2018.
-
30.
Mackey TK, Nayyar G, 2016. Digital danger: a review of the global public health, patient safety and cybersecurity threats posed by illicit online pharmacies. Br Med Bull 118: 110–126.
-
31.
FDA, 2017. FDA Conducts Major Global Operation to Protect Consumers from Potentially Dangerous Prescription Drugs Sold Online. FDA News Release; September 25, 2017. Available at: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm577178.htm. Accessed September 20, 2018.
-
32.
FDA, 2017. Fact Sheet. Available at: https://www.fda.gov/downloads/AboutFDA/Transparency/Basics/UCM553532.pdf. Accessed September 20, 2018.
-
33.
Preston C, Chahal HS, Porras A, Cargill L, Hinds M, Olowokure B, Cummings R, Hospedales J, 2016. Regionalization as an approach to regulatory systems strengthening: a case study in CARICOM member states. Rev Panam Salud Publica 39: 262–268.
-
34.
Strachan J, 2017. Harmonization: Regulation Goes Global. Available at: https://themedicinemaker.com/issues/0917/harmonization-regulation-goes-global/. Accessed September 20, 2018.
-
35.
Seiter A, 2012. Medicines Regulation, Regulatory Harmonization, Global Initiatives–Presentation. Available at: http://www.who.int/medicines/areas/policy/IPC_dec2012_Seiter_reg.pdf. Accessed September 18, 2018.
-
36.
Hajjou M et al. 2015. Monitoring the quality of medicines: results from Africa, Asia, and South America. Am J Trop Med Hyg 92: 68–74.
-
37.
FDA, 2017. U.S. FDA International Programs. Available at: https://www.fda.gov/InternationalPrograms/. Accessed September 20, 2018.
-
38.
WHO, 2017. Strengthening Regulation of Medical Products in Bangladesh. Available at: http://www.searo.who.int/bangladesh/cipmeeting/en/. Accessed September 18, 2018.
-
39.
Liang BA, 2008. Pigs, Drugs, and Terrorists. Available at: https://www.psqh.com/analysis/november-december-2008-health-policy/. Accessed September 20, 2018.
-
40.
Partnership for Safe Medicines, 2017. How Can Counterfeit Drugs Be Useful to Terrorists? Available at: http://www.safemedicines.org/counterfeit-drugs-and-terrorism. Accessed September 20, 2018.
-
41.
Attaran A, 2015. Stopping murder by medicine: introducing the model law on medicine crime. Am J Trop Med Hyg 92: 127–132.
-
42.
Attaran Amir. Model Law on Medicine Crime (April 15, 2015). Available at: https://ssrn.com/abstract:2530087 or http://dx.dpi.org/10.2139/SSM.2530087. Accessed February 16, 2019.
-
43.
Kovacs S, Hawes SE, Maley SN, Mosites E, Wong L, Stergachis A, 2014. Technologies for detecting falsified and substandard drugs in low and middle-income countries. PLoS One 9: e90601.
-
44.
Taylor D, 2014. RFID in the pharmaceutical industry: addressing counterfeits with technology. J Med Syst 38: 141.
-
45.
Mackey TK, Nayyar GA, 2017. Review of existing and emerging digital technologies to combat the global fake medicines trade. Expert Opin Drug Safe 16: 587–602.
-
46.
Marr B, 2016. How Blockchain Technology Could Change the World. Available at: http://www.forbes.com/sites/bernardmarr/2016/05/27/how-blockchain-technology-could-change-the-world/. Accessed September 18, 2018.
-
47.
IOM; Buckley GJ, Gostin LO, 2013. Countering the Problem of Falsified and Substandard Drugs. Washington, DC: National Academies Press.
-
48.
UN, 2015. Sustainable Development Goals. Available at: https://sustainabledevelopment.un.org/sdgs. Accessed September 18, 2018.
-
49.
Nayyar GML, Breman JG, Herrington JE, 2015. The global pandemic of falsified medicines: laboratory and field innovations and policy perspectives. Am J Trop Med Hyg 92: 2–7.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 51 | 51 | 51 |
| Full Text Views | 4278 | 1376 | 53 |
| PDF Downloads | 1900 | 662 | 34 |
Falsified and Substandard Drugs: Stopping the Pandemic
Falsified and substandard medicines are associated with tens of thousands of deaths, mainly in young children in poor countries. Poor-quality drugs exact an annual economic toll of up to US$200 billion and contribute to the increasing peril of antimicrobial resistance. The WHO has emerged recently as the global leader in the battle against poor-quality drugs, and pharmaceutical companies have increased their roles in assuring the integrity of drug supply chains. Despite advances in drug quality surveillance and detection technology, more efforts are urgently required in research, policy, and field monitoring to halt the pandemic of bad drugs. In addition to strengthening international and national pharmaceutical governance, in part by national implementation of the Model Law on Medicines and Crime, a quantifiable Sustainable Development Goal target and an international convention to insure drug quality and safety are urgent priorities.
Author Notes
Senior Scientist Emeritus, FIC, NIH (retired).
Authors’ addresses: Gaurvika M. L. Nayyar, Syneos Health Commercial Solutions, San Francisco, CA, E-mail: gaurvika@gmail.com. Joel G. Breman, National Institutes of Health, Fogarty International Center, Bethesda, MD, E-mail: bremanj@mail.nih.gov. Tim K. Mackey, Department of Anesthesiology, UC San Diego, La Jolla, CA, E-mail: tmackey@ucsd.edu. John P. Clark, Pfizer Pharmaceuticals, Pfizer Global Security, New York, NY, E-mail: john.clark@pfizer.com. Mustapha Hajjou, Global Health Impact Programs, U.S. Pharmacopeial Convention, Rockville, MD, E-mail: mh@usp.org. Megan Littrell, Public Affairs, PATH, Seattle, WA, E-mail: mlittrell@path.org. James E. Herrington, Department of Health Behavior, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, E-mail: jimhsph@email.unc.edu.